ĐẶC ĐIỂM LÂM SÀNG VÀ NỒNG ĐỘ CALPROTECTIN CỦA BỆNH NHÂN BỆNH LÝ RUỘT VIÊM ĐIỀU TRỊ TẠI BỆNH VIỆN TRUNG ƯƠNG THÁI NGUYÊN

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Hồng Thái Dương, Thị Hương Lan Lê, Hải Yến Nguyễn

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Tạp chí Khoa học và Công nghệ - Đại học Thái Nguyên, 2023

Mô tả vật lý: tr.37-45

Bộ sưu tập: Metadata

ID: 339731

Thêm vào giỏ Liên kết toàn văn

Nghiên cứu nhằm mô tả đặc điểm lâm sàng và nồng độ calprotectin của bệnh nhân ruột viêm. Nghiên cứu sử dụng phương pháp nghiên cứu mô tả cắt ngang trên 34 bệnh nhân mắc IBD và 20 bệnh nhân bị viêm ruột kích thích (nhóm chứng) được thăm khám lâm sàng và định lượng calprotectin trong phân trên máy miễn dịch tự động LAISON-XL. Kết quả nghiên cứu cho thấy nồng độ Calprotetin trung bình xác định nhóm bệnh IBD và nhóm chứng lần lượt là: 113,0 ± 110,9 mg/kg
35,6 ± 21,6 mg/kg. Nồng độ calprotectin ở bệnh nhân viêm ruột IBD cao hơn rõ rệt ở nhóm chứng với <
0,001. Tỷ lệ bệnh nhân IBD có nồng độ calprotectin từ 50-120 mg/kg chiếm 58,8%, tỷ lệ bệnh nhân có nồng độ calprotectin ≥ 120 mg/kg là 26,5%. Nhóm bệnh nhân IBD, thời gian mắc bệnh trên 10 năm chiếm tỷ lệ cao nhất (44,1%), triệu chứng đi đại tiện nhiều lần từ 3-4 lần/ngày, phân có máu chiếm tỷ lệ cao. Dựa trên điểm Mayo trên lâm sàng, mức độ hoạt động bệnh nhẹ chiếm 23,5%, mức độ hoạt động bệnh vừa chiếm 41,3% và hoạt động bệnh nặng chiếm 35,3%. Kết quả nội soi cho thấy, thể tổn thương viêm loét trực tràng ít gặp nhất (20,6%)
thể viêm loét đại tràng trái (41,2%), thể viêm loét đại tràng lan rộng (38,2%). Trong đó, bệnh nhân ở giai đoạn 2 qua hình ảnh nội soi theo Baron chiếm 44,1%, giai đoạn 3 là 29,4% và chỉ có 23,5% người bệnh ở giai đoạn 0.This study aimed to describe clinical characteristics and determine the concentration of Calprotectin in the stool of Inflammatory Bowel Diseases (IBD). This study was a cross-sectional analysis of 34 patients with IBD and 20 patients with irritable bowel disease (control group) were clinically examined and collected stool samples from patients who tested Calprotectin on the LAISON-XL automated immunoassay. The results showed that the average Calprotetin concentration determining the IBD group and the control group was: 113.0±110.9mg/kg, respectively
35.6±21.6 mg/kg. Calprotectin concentrations in patients with IBD were significantly higher than in controls with <
0.001. The proportion of IBD patients with calprotectin concentration from 50-120 mg/kg, accounting for 58.8%, the proportion of patients with calprotectin concentration ≥ 120 mg/kg was 26.5%. The duration of the disease over 10 years accounted for the highest proportion (44.1%), symptoms of frequent bowel movements 3-4 times/day, bloody stools accounted for a high proportion. Based on clinical Mayo scores, mild disease activity accounted for 23.5%, moderate disease activity accounted for 41.3% and severe disease activity accounted for 35.3%. Endoscopic results rectal ulcerative lesions are the least common (20.6%). Left ulcerative colitis (41.2%), widespread ulcerative colitis (38.2%). In which, patients in stage 2 through Baron's endoscopic image accounted for 44.1%, stage 3 was 29.4% and only 23.5% of patients in stage 0.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR